Alkaptonuria: Diagnosis and Management
Alkaptonuria is diagnosed by detecting elevated homogentisic acid (HGA) in urine (which darkens upon standing) and confirmed by genetic testing for HGD gene mutations, with treatment centered on nitisinone therapy to reduce HGA accumulation and prevent ochronotic complications. 1, 2
Diagnostic Approach
Initial Recognition
Look for the pathognomonic sign: dark urine that turns black/brown after several hours of exposure to air due to HGA oxidation 1, 3, 4. This is often the first presenting feature, particularly in childhood, though diagnosis is frequently delayed due to lack of physician awareness 1, 3.
Biochemical Confirmation
- Qualitative urine test: Observe urine darkening after atmospheric exposure 4
- Quantitative HGA measurement: Elevated urinary HGA levels confirm the diagnosis 1, 2
- Genetic testing: Identify pathogenic variants in the HGD gene via molecular sequencing (exome or targeted gene panels) 3, 4, 5
Common Mutations
The most frequent mutation is c.175delA, followed by c.674G>A and c.1007-2A>T 3. Genetic confirmation is essential for definitive diagnosis and family counseling.
Clinical Manifestations to Monitor
Early Signs (Childhood to Second Decade)
- Dark urine (may be present from infancy)
- Occasionally: joint pain, low back pain, or renal stones even before ochronosis becomes evident 3
Later Manifestations (Third Decade Onward)
- Ochronosis: Dark pigmentation in cartilage, sclera, and ear cartilage 1, 6
- Ochronotic arthropathy: Severe, painful joint destruction affecting large joints and spine 1, 6
- Cardiovascular: Aortic valve stenosis 1, 6
- Renal/urologic: Kidney and prostate stones 1, 3
- Musculoskeletal: Tendon/ligament ruptures, fractures, osteoporosis 1, 6
- Neuropsychiatric: Depression has been documented 3
Treatment Strategy
Primary Pharmacologic Therapy: Nitisinone
Nitisinone is the first-line treatment, approved in the European Union since 2020, which significantly reduces HGA production and arrests ochronosis progression 2, 7, 5. This medication blocks the tyrosine metabolic pathway upstream of HGA formation.
Critical caveat: Nitisinone causes hypertyrosinemia, which can lead to corneal keratopathy requiring treatment interruption 7, 5. Monitor tyrosine levels closely and implement dietary protein restriction if levels become problematic.
Dietary Management
- Protein restriction: Reduces tyrosine substrate and mitigates nitisinone-induced hypertyrosinemia 7, 4
- Vitamin C supplementation: Acts as an antioxidant to counteract HGA-induced oxidative stress 4
Important pitfall: Prolonged low-protein diets cause muscle loss and weight gain from compensatory carbohydrate/fat intake 7. Balance protein restriction carefully and monitor nutritional status.
Supportive and Symptomatic Care
- Physical therapy: Maintain joint function and mobility 1
- Pain management: Address chronic joint pain from ochronotic arthropathy
- Surgical intervention: Joint replacement surgery for severe arthropathy (21.2% of patients in one series required surgery) 3
- Ophthalmologic monitoring: Regular slit-lamp examinations to detect corneal keratopathy if on nitisinone 7
Monitoring Protocol
Baseline Assessment
- Comprehensive joint and spine evaluation
- Cardiac ultrasound (assess for valvular disease)
- Renal ultrasound (detect stones/structural abnormalities)
- Ophthalmologic examination (baseline before nitisinone)
- Urinary HGA levels
- Plasma tyrosine levels (if starting nitisinone)
Ongoing Surveillance
- Every 3-6 months: Plasma tyrosine levels (on nitisinone), urinary HGA levels, joint symptoms assessment
- Annually: Cardiac evaluation, renal imaging, ophthalmologic examination (especially on nitisinone), bone density assessment
- As needed: Psychiatric evaluation for depression, orthopedic consultation for fractures/ruptures
Multidisciplinary Team
Coordinate care among genetics, rheumatology, cardiology, nephrology, ophthalmology, orthopedics, and nutrition specialists 1, 5.
Prognosis and Quality of Life
Without treatment, debilitating symptoms emerge around the third decade, with progressive deterioration in quality of life from chronic pain, joint destruction, and cardiovascular complications 1, 6. Early diagnosis and nitisinone initiation can stabilize disease manifestations and prevent irreversible ochronotic damage 2, 5.
The key to optimal outcomes is early recognition (ideally before ochronosis develops), prompt genetic confirmation, and timely nitisinone initiation with careful monitoring for hypertyrosinemia 1, 2, 4.